Pure Global
NCT06421948

Linperlisib Combined With Chidamide in Patients With PTCL

PI3Kδ Inhibitor Linperlisib Combined With HDAC Inhibitor Chidamide Versus CHOP in Patients With Peripheral T-cell Lymphoma: a Multicenter, Open Label, Phase Ib/II Study
Yanyan Liu·Phase 1/2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral T-cell Lymphoma
Drug/Device/Intervention
Linperlisib and chidamide
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Yanyan Liu
Funder
Henan Cancer Hospital
Location
Zhengzhou, China
Timeline & enrollment
Phase
Phase 1/2
Start date
Jan 01, 2024
End date
May 31, 2026
Enrollment
100 participants
Primary outcome

CRR

Summary

The goal of this clinical trial is to determine the maximum tolerated dose (MTD) of PI3Kδ
 inhibitor linperlisib when combined with fixed dose of HDAC inhibitor chidamide in
 participants with peripheral T-cell lymphoma (PTCL), and to compare the combination of
 linperlisib and chidamide to standard CHOP (cyclophosphamide, doxorubicin/epirubicin,
 vincristine, and prednisone) regimen chemotherapy in the frontline treatment of PTCL to see
 which therapy is better.

ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06421948
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06421948 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Yanyan Liu and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.